Study: NCT04978454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza RG-A/Texas/71/2017 (H3N2) Challenge
Description: RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza RG-A/Texas/71/2017 (H3N2) Challenge
Description: RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza RG-A/Texas/71/2017 (H3N2) Challenge
Description: RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza RG-A/Texas/71/2017 (H3N2) Challenge
Description: RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza RG-A/Texas/71/2017 (H3N2) Challenge
Description: RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza RG-A/Texas/71/2017 (H3N2) Challenge
Description: RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza RG-A/Texas/71/2017 (H3N2) Challenge
Description: RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza RG-A/Texas/71/2017 (H3N2) Challenge
Description: RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose phosphate glutamate (SPG) inoculum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose phosphate glutamate (SPG) inoculum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose phosphate glutamate (SPG) inoculum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose phosphate glutamate (SPG) inoculum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose phosphate glutamate (SPG) inoculum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose phosphate glutamate (SPG) inoculum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose phosphate glutamate (SPG) inoculum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose phosphate glutamate (SPG) inoculum